StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) stock

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.46−0.09 (-15.97%)

Close on Nov 17, 2026Market cap $830.71KP/E –Yield –

Aptevo Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Aptevo Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$25.34M. For fiscal 2025 it was -$25.59M. The highest annual figure on record is -$11.73M in fiscal 2023.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$25.59M–
FY2024Dec 31, 2024-$23.79M–
FY2023Dec 31, 2023-$11.73M–
FY2022Dec 31, 2022-$21.02M–
FY2021Dec 31, 2021-$21.68M–
FY2020Dec 31, 2020-$29.32M–
FY2019Dec 31, 2019-$42.38M–
FY2018Dec 31, 2018-$51.42M–
FY2017Dec 31, 2017-$41.57M–
FY2016Dec 31, 2016-$36.86M–
FY2015Dec 31, 2015-$48.76M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.45M–
Q1 FY2026Mar 31, 2026-$7.97M–
Q4 FY2025Dec 31, 2025-$5.24M–
Q3 FY2025Sep 30, 2025-$6.69M–
Q2 FY2025Jun 30, 2025-$7.09M–
Q1 FY2025Mar 31, 2025-$6.58M–
Q4 FY2024Dec 31, 2024-$5.76M–
Q3 FY2024Sep 30, 2024-$5.22M–
Q2 FY2024Jun 30, 2024-$6.15M–
Q1 FY2024Mar 31, 2024-$6.65M-245.7%
Q4 FY2023Dec 31, 2023-$5.25M–
Q3 FY2023Sep 30, 2023-$6.24M–
Q2 FY2023Jun 30, 2023-$4.80M–
Q1 FY2023Mar 31, 2023$4.57M–
Q4 FY2022Dec 31, 2022-$5.94M–
Q3 FY2022Sep 30, 2022-$6.90M–
Q2 FY2022Jun 30, 2022-$3.07M–
Q1 FY2022Mar 31, 2022-$5.12M–
Q4 FY2021Dec 31, 2021-$3.88M–
Q3 FY2021Sep 30, 2021-$5.24M–
Q2 FY2021Jun 30, 2021-$5.05M–
Q1 FY2021Mar 31, 2021-$7.50M–
Q4 FY2020Dec 31, 2020-$6.12M–
Q3 FY2020Sep 30, 2020-$7.39M–
Q2 FY2020Jun 30, 2020-$4.63M–
Q1 FY2020Mar 31, 2020-$11.18M–
Q4 FY2019Dec 31, 2019-$5.10M–
Q3 FY2019Sep 30, 2019-$7.55M–
Q2 FY2019Jun 30, 2019-$15.89M–
Q1 FY2019Mar 31, 2019-$13.84M–
Q4 FY2018Dec 31, 2018-$7.29M–
Q3 FY2018Sep 30, 2018-$11.15M–
Q2 FY2018Jun 30, 2018-$16.01M–
Q1 FY2018Mar 31, 2018-$16.98M–
Q4 FY2017Dec 31, 2017-$15.42M–
Q3 FY2017Sep 30, 2017-$1.62M–
Q2 FY2017Jun 30, 2017-$12.51M–
Q1 FY2017Mar 31, 2017-$12.03M–
Q4 FY2016Dec 31, 2016-$6.67M–
Q3 FY2016Sep 30, 2016-$134.00K–

More Aptevo Therapeutics figures

See a number that looks wrong?